HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nutt, J. G. Articles by Carter, J. H. Search for Related Content PubMed PubMed Citation Articles by Nutt, J. G. Articles by Carter, J. H.

Clinical and biochemical studies with controlled-release levodopa/carbidopa

Oregon Health Sciences University, Portland, OR.

In five patients with parkinsonism, the optimal dosage of a controlled-release levodopa/carbidopa preparation (CR-3) was three times higher than the dosage of Sinemet and produced higher plasma levodopa concentrations, but did not reduce the fluctuations in plasma levodopa or clinical response. Plasma levodopa concentrations were higher and clinical responses better before the first dose of the day with CR-3. CR-3 treatment benefited two patients, reducing the severity of off periods and off dystonia. Two patients were worse on CR-3 despite higher plasma levodopa levels than those adequate for clinical response to Sinemet or levodopa infusions. CR-3 could benefit a few severely affected patients, but it is necessary to understand the factors that affect absorption of levodopa from sustained-release preparations, as well as the consequences of prolonged elevation of plasma levodopa levels.

Address correspondence and reprint requests to Dr. Nutt, Oregon Health Sciences University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97201.

Supported in part by NINCDS 1 RO1 NS 21062–01, Clinical Centers Grant RR00334, and Merck Sharp & Dohme Laboratories.

Accepted for publication December 28, 1985.

This article has been cited by other articles:

				J. G. Nutt, J. H. Carter, and N. E. Carlson Effects of Methylphenidate on Response to Oral Levodopa: A Double-blind Clinical Trial Arch Neurol, March 1, 2007; 64(3): 319 - 323. [Abstract] [Full Text] [PDF]

				S. Dethy, M. A. Laute, N. Van Blercom, P. Damhaut, S. Goldman, and J. Hildebrand Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients Clin. Chem., May 1, 1997; 43(5): 740 - 744. [Abstract] [Full Text] [PDF]

				P. J. Karstaedt, J. H. Pincus, and S. S. Coughlin Standard and Controlled-Release Levodopa/Carbidopa in Patients With Fluctuating Parkinson's Disease on a Protein Redistribution Diet: A Preliminary Report Arch Neurol, April 1, 1991; 48(4): 402 - 405. [Abstract] [PDF]

				J. T. Hutton, J. L. Morris, G. C. Roman, S. C. Imke, and J. W. Elias Treatment of Chronic Parkinson's Disease With Controlled-Release Carbidopa/Levodopa Arch Neurol, August 1, 1988; 45(8): 861 - 864. [Abstract] [PDF]

				J. L. Juncos, G. Fabbrini, M. M. Mouradian, and T. N. Chase Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations Arch Neurol, October 1, 1987; 44(10): 1010 - 1012. [Abstract] [PDF]